Leonabio, Inc.

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer